Clinical trials
Locally Advanced Lung Carcinoma clinical trials
Below are recruiting locally advanced lung carcinoma clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Denver, ColoradoAges 18 years+ - NCT07330050RecruitingPhase 2
Combination treatment for advanced lung cancer after immunotherapy failure
This trial tests a combination of WAST Cell therapy and the chemotherapy drug docetaxel for people with advanced non-small cell lung cancer whose cancer progressed after treatment with a PD-1 inhibitor. The goal is to see if this combination can help shrink tumors and extend survival.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07315750RecruitingPhase 3
Study of three drugs vs standard care for HER2-high stomach cancer
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
Beijing, BJ-BeijingAges 18–75 - NCT07235930RecruitingPhase 3
New drug combo for advanced pancreatic cancer
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
Hangzhou, ZhejiangAges 18–75 - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07124000Recruiting
T-DXd for advanced HER2-positive solid tumors
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
Birmingham, AlabamaAges 18–130 - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT07140016RecruitingPhase 1
Study of gilteritinib for advanced ALK-positive lung cancer
This trial tests an oral drug called gilteritinib for people with advanced ALK-positive non-small cell lung cancer that has progressed after prior ALK inhibitor treatment. It aims to see if gilteritinib can help when other treatments have stopped working.
Fullerton, CaliforniaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT07814248RecruitingPhase 1
TS-104 for advanced solid tumors
This trial tests a new drug called TS-104 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is given alone (not with other cancer treatments) to see if it can shrink tumors or slow their growth.
Maumee, OhioAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT07354919RecruitingPhase 2
Testing axelopran for advanced cancer patients on opioids
This trial tests if axelopran can help people with advanced prostate, breast, pancreatic, or lung cancer who are taking opioid pain medicines. It aims to see if the drug is safe and helps with bowel function.
Saint Louis Park, MinnesotaAges 18 years+ - NCT06515314RecruitingPhase 1
TCR-T cell therapy for AFP-positive liver and other cancers
This trial tests an experimental cell treatment called HRYZ-T102 TCR-T for people with advanced liver cancer or other solid tumors that make a protein called AFP. The treatment uses your own immune cells, modified in a lab to target and kill cancer cells.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06370416Enrolling by invitationPhase 2
Preventing bone marrow suppression from chemo in advanced lung cancer
This trial tests if trilaciclib can protect your bone marrow during chemotherapy for advanced non-small cell lung cancer. The goal is to reduce side effects like low blood counts, which can cause fatigue, infections, or bleeding.
Zhengzhou, HenanAges 18 years+ - NCT07172802RecruitingPhase 1/Phase 2
Study of GI-108 for advanced solid tumors
This trial tests a new drug called GI-108, which is designed to help your immune system fight cancer. It is for people with advanced or metastatic solid tumors that have not responded to other treatments.
SeoulAges 18 years+ - NCT06639191RecruitingEarly Phase 1
Study of a new drug for cancers expressing CD44v6
This trial tests a new radioactive drug called [177Lu]Lu-AKIR001 for patients with certain advanced cancers (like thyroid, head and neck, lung, vulvar, or cervical cancer) that have a specific protein called CD44v6 on their surface. The goal is to see if this treatment can help when standard options have stopped working.
Stockholm, Stockholm CountyAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced lung carcinoma?
- Yes. Clin2 currently lists 549 recruiting locally advanced lung carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced lung carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced lung carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Rectal Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Nasopharyngeal Carcinoma
- Locally Advanced Cervical Carcinoma
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.